Proteasome Inhibitor Anticancer Drug Bortezomib Redox Behaviour at a Glassy Carbon Electrode

Bortezomib is the first therapeutic proteasome inhibitor used for cancer treatment. The redox behaviour of bortezomib was investigated over a wide pH range. Bortezomib undergoes electrochemical oxidation and reduction in independent mechanisms. The oxidation of bortezomib is pH‐dependent for pH

Saved in:
Bibliographic Details
Published in:Electroanalysis (New York, N.Y.) N.Y.), 2012-10, Vol.24 (10), p.1915-1921
Main Authors: Golea, Diana Andreea, Diculescu, Victor C., Tugulea, Laura, Oliveira Brett, Ana Maria
Format: Article
Language:English
Subjects:
Bortezomib
Cancer treatment
Inhibitor
Proteasome
Voltammetry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bortezomib is the first therapeutic proteasome inhibitor used for cancer treatment. The redox behaviour of bortezomib was investigated over a wide pH range. Bortezomib undergoes electrochemical oxidation and reduction in independent mechanisms. The oxidation of bortezomib is pH‐dependent for pH
ISSN:1040-0397
1521-4109
DOI:10.1002/elan.201200307